Shady Grove Fertility, Rockville, MD, USA.
Reprod Biomed Online. 2013 Jan;26(1):50-8. doi: 10.1016/j.rbmo.2012.09.014. Epub 2012 Sep 26.
A retrospective analysis of a large, randomized clinical trial (Engage) assessed whether adjusting the start day of ovarian stimulation and/or day of human chorionic gonadotrophin (HCG) trigger could minimize oocyte retrieval during weekends without adverse effects on clinical outcome. Patients received recombinant FSH/gonadotrophin-releasing hormone (GnRH) antagonist regimens, with stimulation starting on day 2 or 3 of menses. HCG was administered when at least three follicles of ⩾ 17 mm were present on ultrasound scan or 1 day later. The frequency distribution of the day of reaching the HCG criterion relative to stimulation initiation was analysed to determine the optimal stimulation start day (cycle day 2 or 3) depending on the weekday at which menses started, to minimize weekend retrieval. The number of oocytes retrieved and pregnancy rates were not affected by start day and/or delay in HCG administration in regularly ovulating women aged 18-36 years with bodyweight 60-90 kg, body mass index 18-32 kg/m(2) and menstrual cycle length 24-35 days. In recombinant FSH/GnRH antagonist regimens, it appears possible to minimize weekend oocyte retrieval by selecting the cycle day to initiate stimulation, day 2 when menses starts Friday-Tuesday, otherwise day 3 and if necessary in combination with a 1-day HCG delay. A retrospective analysis of the data collected from a large, randomized clinical trial (Engage) was conducted to assess whether adjusting the start day of ovarian stimulation and/or the day of human chorionic gonadotrophin (HCG) trigger could minimize the possibility of retrieving the mature egg cells during weekends, without an adverse effect on the clinical outcome. Patients were administered recombinant FSH/gonadotrophin-releasing hormone (GnRH) antagonist on either day 2 or 3 of menses in order to start ovarian stimulation. Ultrasound monitoring was subsequently performed to determine when at least three follicles of ⩾17 mm or more in diameter were present, and final maturation was induced by HCG administration either on that day or 1 day later, if necessary. The frequency distribution of day of reaching HCG criterion relative to ovarian stimulation initiation on cycle day 2 or 3 was analysed to determine the optimal ovarian stimulation day (day 2 or 3) depending on the weekday at which the menses started to minimize the possibility of weekend egg retrieval. Number of eggs retrieved and pregnancy rates were not found to be affected by day of stimulation and/or a 1-day delay in HCG administration. In a recombinant FSH/GnRH antagonist protocol, weekend egg retrieval can be minimized by selecting the appropriate cycle day to initiate ovarian stimulation (cycle day 2 when menses starts Friday to Tuesday, otherwise cycle day 3), and if necessary in combination with a 1-day HCG delay.
一项针对大型随机临床试验(Engage)的回顾性分析评估了调整卵巢刺激启动日和/或人绒毛膜促性腺激素(hCG)扳机日是否可以在不影响临床结局的情况下,尽量减少周末取卵。患者接受重组卵泡刺激素/促性腺激素释放激素(GnRH)拮抗剂方案,于月经第 2 或 3 天开始刺激。当超声扫描显示至少有三个 ⩾17mm 的卵泡或 1 天后,给予 hCG。分析达到 hCG 标准的日期相对于刺激开始的频率分布,以确定最佳的刺激启动日(第 2 天或第 3 天),以尽量减少周末取卵。在体重 60-90kg、体重指数 18-32kg/m2 和月经周期 24-35 天的 18-36 岁正常排卵、体重正常的女性中,启动日和/或 hCG 给药延迟对取卵数和妊娠率没有影响。在重组 FSH/GnRH 拮抗剂方案中,通过选择启动刺激的周期日、周五至周二开始月经的第 2 天、否则第 3 天以及必要时结合 1 天 hCG 延迟,可以最大限度地减少周末取卵。对一项大型随机临床试验(Engage)收集的数据进行了回顾性分析,以评估调整卵巢刺激启动日和/或人绒毛膜促性腺激素(hCG)扳机日是否可以尽量减少周末取成熟卵的可能性,而不影响临床结局。患者在月经第 2 天或第 3 天开始接受重组卵泡刺激素/促性腺激素释放激素(GnRH)拮抗剂,以启动卵巢刺激。随后进行超声监测,以确定至少有三个 ⩾17mm 或更大直径的卵泡。如果需要,当天或第 1 天给予 hCG 诱导最终成熟。分析达到 hCG 标准的日期相对于周期第 2 天或第 3 天启动卵巢刺激的频率分布,以确定最佳的卵巢刺激日(第 2 天或第 3 天),以尽量减少周末取卵的可能性。启动日和/或 hCG 给药延迟 1 天对取卵数和妊娠率没有影响。在重组 FSH/GnRH 拮抗剂方案中,通过选择合适的周期日启动卵巢刺激(周五至周二开始月经的第 2 天,否则第 3 天),并在必要时结合 1 天 hCG 延迟,可以尽量减少周末取卵。